Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs SPB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SPB's multiple
Needs SPB P/E.
Implied fair value · at HCA's multiple
Needs HCA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
Spectrum Brands Holdings, Inc. · implied price per share
Bear
-$15.74
Base
-$15.50
Bull
-$15.07
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
NEWELL BRANDS INC.
HCA vs NWL
JAKKS PACIFIC INC
HCA vs JAKK
WHIRLPOOL CORP /DE/
HCA vs WHR
IROBOT CORP
HCA vs IRBT
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA can sustain 7.1% revenue growth and preserve its 9.0% net margin, then HCA looks attractive to own because it trades at a lower 14.5x P/E than SPB while still showing stronger profitability and a valuation below the DCF range.
HCA's current price of $410.54 sits below the DCF range midpoint and below the top of its historical band, while the implied P/E value suggests meaningful upside to $623.92. On relative multiples, HCA trades at 14.5x P/E versus SPB's 22.0x, despite HCA's superior revenue growth and net margin.
Supporting Metrics
